) and PGE 2 are abundantly present in the synovial fl uid of rheumatoid arthritis (RA) patients. Although the role of PGE 2 in RA has been well studied, how much PGI 2 contributes to RA is little known. To examine this issue, we backcrossed mice lacking the PGI receptor (IP) to the DBA/1J strain and subjected them to collagen-induced arthritis (CIA). IP-defi cient (IP −/− ) mice exhibited signifi cant reduction in arthritic scores compared with wild-type (WT) mice, despite anti-collagen antibody production and complement activation similar to WT mice. IP −/− mice also showed signifi cant reduction in contents of proinfl ammatory cytokines, such as interleukin (IL)-6 in arthritic paws. Consistently, the addition of an IP agonist to cultured synovial fi broblasts significantly enhanced IL-6 production and induced expression of other arthritis-related genes. On the other hand, loss or inhibition of each PGE receptor subtype alone did not affect elicitation of infl ammation in CIA. However, a partial but signifi cant suppression of CIA was achieved by the combined inhibition of EP2 and EP4. Our results show signifi cant roles of both PGI 2 -IP and PGE 2 -EP2/EP4 signaling in the development of CIA, and suggest that inhibition of PGE 2 synthesis alone may not be suffi cient for suppression of RA symptoms.
Rheumatoid arthritis (RA) is a chronic infl ammatory disease of the joint characterized by infl ammatory cell infi ltration, synovial lining hyperplasia, and destruction of cartilage and bone. Although the etiology of RA has not yet been fully understood, recent studies have suggested the involvement of autoantibody production, immune complex formation, infl ammatory cell infi ltration, and tumor-like proliferation of synovium in the pathogenesis of RA (1) (2) (3) (4) . Autoantibodies, such as rheumatoid factor (anti-IgG antibody) and anti-type II collagen (CII) antibody, are detected in RA patients with high probability. These autoantibodies make immune complexes within the joint, leading to activation of the complement cascade and infl ammatory cell infi ltration into the joint. Particular attention is now paid to the network of cytokines, chemokines, and growth factors in the development of RA (5, 6) . Infi ltrated macrophages and neutrophils release IL-1β, which activates synovial cells. Activated synovial cells then produce various chemokines, cytokines, and growth factors. Chemokines such as CCL2 (monocyte chemoattractant protein 1 [MCP-1]) and CCL3 (macrophage infl ammatory protein 1α) produced by synovial cells further recruit infl ammatory cells into the joint (7) , and IL-6 and fi broblast growth factors (FGFs) produced by synovial cells contribute to their proliferation in an autocrine manner (8) . IL-6 also induces both B and T cell activation and osteoclast formation. These positive-feedback loops amplify infl ammation and de struction within the joint.
Collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA) are the widely used arthritis models in the mouse. CIA is induced by immunizing mice with CII, whereas CAIA is induced by the administration of a combination of monoclonal anti-CII antibodies and LPS. CAIA can be induced in various mouse strains with rapid onset compared with that of CIA. However, the lesions of CAIA are milder and its symptoms last for a shorter duration than CIA (9) . Furthermore, an acute induction of CAIA by LPS injection may not mimic the natural course and mechanisms in RA development. On the other hand, although the induction of CIA is limited to a few mouse strains such as DBA/1J and takes about a month to develop, its lesions last for a long time and its histopathology, characterized by synovitis, pannus formation, cartilage erosion, and bone destruction in joints, is quite similar to that of human RA (10) . Therefore, CIA is an arthritis model suitable for analyzing chronic joint infl ammation.
Prostanoids, including prostaglandin (PG)D 2 , PGE 2 , PGF 2α , prostacyclin (PGI) 2 , and thromboxane A 2 , are lipid mediators produced by sequential catalysis of cyclooxygenase (COX) and the respective synthase (11) . They are produced in large amounts at infl ammatory sites in response to various stimuli. Nonsteroidal antiinfl ammatory drugs (NSAIDs) that inhibit COX and suppress PG production have been long and widely used for the treatment of RA. NSAIDs reduce the extent and number of tender or swollen joints in RA patients, implicating PGs in pain and infl ammation of RA. Consistently, an inducible form of COX, COX-2, is expressed in the infl ammatory synovium of RA patients (12) . Among PGs, PGE 2 has been suggested as a main PG species working in RA reactions because PGE 2 is detected as one of the major PGs in the synovial fl uid in RA patients (13) and shows pleiotropic proinfl ammatory actions in vitro (for example, see reference 14) . Recently, it has also been reported that mice defi cient in microsomal PGE synthase (mPGES)-1 −/− showed reduced arthritic responses in CIA (15) . On the other hand, although PGI 2 is known as another major prostanoid, often detected more abundantly than PGE 2 in the synovial fl uid of RA patients (13), whether PGI 2 contributes to the development of arthritis has not been tested extensively. Prostanoids exert their actions via a family of G protein-coupled receptors, (11) , which include PGD receptor (DP), four subtypes of PGE receptor (EP1, EP2, EP3, and EP4), PGF receptor (FP), PGI receptor (IP), and thromboxane A receptor (TP). We have generated mice defi cient in each of the PG receptor types and subtypes individually and subjected them to various disease models to defi ne the roles of each PG (16) (17) (18) (19) . Using mice lacking the IP, we previously showed the role of PGI 2 as a mediator of acute infl ammation induced by bradykinin or carrageenin, and of acute pain response to acetic acid (16) . In this study, we have subjected IP-defi cient mice (IP −/− ) to CIA and examined the roles of PGI 2 in this model. We have further compared the phenotype of IP −/− mice with those of mice lacking one of the PGE receptor subtypes (EP1, EP2, or EP3) and/or mice administered with an EP4-selective antagonist.
RESULTS

Involvement of PGI 2 -IP signaling in CIA
To examine how PGI 2 contributes to the development of CIA, we backcrossed mice defi cient in IP to the DBA/1J background for 10 generations. CIA was induced by intradermal injection of CII with CFA on day 0, followed by a booster injection of CII with IFA on day 21. Arthritic lesion of each paw was evaluated from day 21 for the extent of swelling, erythema, and deformity, and graded on a scale of 0-4. The sum of scores obtained from four paws was used as the arthritic score of each mouse. The arthritic lesions appeared around day 25 in WT mice, and by day 35 ‫%09ف‬ of the mice developed arthritis. Although the incidence of mice showing more than 1 arthritic score was not diff erent between WT and IP −/− mice (Fig. 1 A) , the arthritic score in IP −/− mice 
ARTICLE
was signifi cantly lower than that of WT mice all through the elicitation phase (Fig. 1 B) . To examine if this phenotype of IP −/− mice refl ects the role of IP in the antibody-mediated eff ector mechanisms of infl ammation, we applied CAIA to IP −/− mice. The CAIA model bypasses the immunization phase by direct injection of monoclonal anti-CII antibodies. IP −/− mice again showed a signifi cant reduction in the arthritic score compared with that of WT mice, although the extent of the reduction was milder than that in CIA (Fig. 1  C) . These results show that the PGI 2 -IP signaling works substantially in the pathogenesis of both CIA and CAIA, and the fi ndings in CAIA suggest the role of this signaling in the antibody-induced infl ammatory responses. Next, we examined if the PGI 2 -IP signaling also works in the immunization of mice in CIA. Sensitization to CII and a consecutive anti-CII antibody production are important steps in the development of CIA. We collected sera from immunized WT and IP −/− mice on day 21 and measured anti-CII antibody titers. The levels of anti-CII antibody in the total IgG fraction and each of the IgG2a, IgG2b, and IgG1 subclasses were similar in WT and IP −/− mice (Fig. 1 D) . These results demonstrate that the loss of IP does not impair anti-CII antibody production in CIA.
Histology of CIA in IP −/− mice To evaluate arthritic lesions in WT and IP −/− mice histologically, we prepared sections of knee joints from WT and IP −/− mice on day 35 and stained them with hematoxylin and eosin (H&E) or toluidine blue (Fig. 2 A) . The arthritic lesion in CIA is characterized by three parameters: cell infi ltration, synovial lining hyperplasia, and tissue destruction. On day 35, joints of WT mice showed characteristic features of CIA in all three parameters: marked infi ltration of infl ammatory cells in the cavity, lining hyperplasia and invasive pannus formation, and bone and cartilage destruction. Compared with these fi ndings in WT mice, IP −/− mice showed markedly reduced infi ltration of infl ammatory cells, less lining hyperplasia, and less destruction of bone and cartilage. When these parameters were graded from 0 to 3 (0, normal; 1, minimal; 2, mild; 3, severe), the score of IP −/− mice in each parameter was signifi cantly lower than that of WT mice (Fig. 2 B) . These results suggest that the PGI 2 -IP signaling acts in promotion of joint infl ammation in CIA.
In CIA, anti-CII antibody produced makes an immune complex with collagen on the cartilage surface of the joint and triggers complement activation, an essential process leading to joint infl ammation in CIA (20) . Large complement fragments such as C3b and C5b accumulate on the cartilage surface, and small complement fragments such as C3a and C5a promote infl ammatory cell infi ltration to the joint. Because the joints of IP −/− mice on day 35 showed markedly reduced infl ammation, we next examined whether the complement activation had occurred on the cartilage surface in IP −/− mice. We examined deposition of C3b on the cartilage surface in the knee joints by immunohistochemistry. No C3b deposition was found on the cartilage surface of naive WT and IP −/− mice (Fig. 2 C , top left and top right, respectively). The deposition of C3b was clearly detected in the WT joint on day 35 ( Fig. 2 C, bottom left) . The joint of IP −/− mice also showed C3b deposition to the extent of that in the WT joint ( Fig. 2 C, bottom right). These results suggest that the loss of IP suppressed the progression of the infl ammatory process despite the equivalent extent of antibody production and complement activation.
Reduced concentrations of proinfl ammatory cytokines in the arthritic paws of IP −/− mice The results described above indicate that the PGI 2 -IP signaling functions in progression or enhancement of the infl ammatory process in CIA. Because proinfl ammatory cytokines such as IL-1β, TNF-α, and IL-6 have been suggested to play important roles in RA (2), we measured the concentrations of these cytokines in the paws of arthritic mice. Paws were collected on day 35 and homogenized. The homogenates were then centrifuged and the supernatants obtained were subjected to ELISA for IL-1β, TNF-α, and IL-6. The concentrations of IL-1β and IL-6 were signifi cantly lower in IP −/− mice than in WT mice (Fig. 3 A) . The concentration of TNF-α was below the detection limit and could not be determined in both groups. To clarify whether the PGI 2 -IP signaling can directly regulate production of these cytokines within the infl ammatory joint, we next prepared arthritic cell suspension, a mixture of synovial cells and various infl ammatory cells from the knee joints of arthritic WT mice on day 35. The eff ects of indomethacin and an IP agonist on IL-1β and IL-6 production by these cells were examined (Fig. 3 B) . As the production of IL-1β by these cells was too low to detect by ELISA under the basal condition, we stimulated them with LPS. LPS induced signifi cant production of IL-1β.However, no signifi cant eff ects of either indomethacin or an IP agonist, cicaprost, were observed on the LPS-induced IL-1β production. On the other hand, the arthritic cell suspension produced a signifi cant amount of IL-6 on a 24-h incubation. The addition of indomethacin significantly suppressed IL-6 production, and the further addition of the IP agonist completely reversed the suppressive eff ect of indomethacin. These results indicate that although endogenous Genes whose expression levels are increased by IL-1β stimulation are clustered fi rst to three groups based on the effect of indomethacin (indo.) treatment (increase, decrease, and no change), and then further grouped into three based on the IP agonist (iloprost) actions. PGs do not directly regulate IL-1β production in arthritic cell suspension, they contribute to IL-6 production, and the PGI 2 -IP signaling can mediate this process. IL-1β and IL-6 are released mainly by infl ammatory cells and synovial cells, respectively (1) . To access whether a reduced IL-1β concentration in IP −/− mice was due to impaired infl ammatory cell infi ltration caused by reduced chemokine production in IP −/− mice, we measured MCP-1 in the arthritic paws of WT and IP −/− mice in the same manner as described above. MCP-1 is one of the chemokines that promotes RA (7, 21) . IP −/− mice showed a signifi cant reduction in the MCP-1 concentration compared with that of WT mice (Fig. 3 C) .
Enhancement of IL-6 production in synovial fi broblasts by PGI 2 -IP signaling The results described above suggest that the PGI 2 -IP signaling facilitates the activation of synovium in infl ammatory joints. Synovial fi broblasts are a major cell population in the synovium and have recently been recognized as one of the pivotal eff ectors in the infl amed joint because of their ability to produce various infl ammatory mediators (1) . To obtain mechanistic insights into the role of IP signaling in synovial activation, we prepared synovial fi broblasts from normal knee joints of WT and IP −/− mice and expanded them by culture. They were then activated by IL-1β for 24 h in the absence or presence of indomethacin and cicaprost, and the eff ects of these compounds on the IL-1β-induced IL-6 production were examined (Fig. 4 A) . IL-1β stimulation signifi cantly increased IL-6 production by synovial fi broblasts from both WT and IP −/− mice. However, the IL-6 production by the IP −/− cells was signifi cantly less than that by the WT fi broblasts, indicating that PGI 2 was endogenously formed by IL-1β stimulation and worked for IL-6 production. This suggestion was supported by an experiment examining the eff ects of indomethacin and cicaprost in WT cells. Indomethacin signifi cantly inhibited IL-6 production in the WT fi broblasts, and the further addition of the IP agonist reversed the inhibition by indomethacin. Cicaprost, on the other hand, had no eff ect on IL-6 production in the IP −/− cells. Notably, the IL-6 production by the indomethacin-treated WT fi broblasts was signifi cantly less than that by the IP −/− cells, and the production of IL-6 by the IP −/− cells was further attenuated by the addition of indomethatcin, suggesting that PGs other than PGI 2 also worked in this process. It was also noted that the treatment of nonactivated WT synovial fi broblasts with cicaprost alone could increase IL-6 production to some extent, and cicaprost further exerted synergistic eff ects with IL-1β (vehicle: 210.9 ± 32.5 pg/ml; cicaprost alone: 1,743.8 ± 127.9 pg/ml; IL-1β alone: 7,858.2 ± 305 pg/ml; cicaprost and IL-1β: 19,179 ± 196.5 pg/ml; Fig. 4, A and B) .
Elevated expression of genes associated with infl ammation, synovial proliferation, and bone destruction by PGI2-IP signaling To evaluate the action of the PGI 2 -IP signaling in synovial fibroblasts in more detail, we next used the microarray analysis using an Aff ymetrix Mouse Genome 430A 2.0 GeneChip that contains ‫000,41ف‬ genes. Synovial fi broblasts were treated with either vehicle, IL-1β, IL-1β with indomethacin, or IL-1β with indomethacin plus an IP agonist (iloprost) for 6 h and used for analysis on the gene expression profi les (see Table S1 , available at http://www.jem.org/cgi/content/ full/jem.20051310/DC1). We used Statistical Algorithm in the Aff ymetrix GeneChip Expression Analysis software and fi rst compared the expression profi le of synovial fi broblasts treated with vehicle and those treated with IL-1β. After exclusion of expressed sequence tags and overlapped genes, we detected 489 genes, the expression of which were statistically increased by the IL-1β treatment. Of the 489 genes, 183 were decreased in their expression by treatment with indomethacin, suggesting that endogenous PG(s) enhances the expression of these genes. Of these 183 genes, the expression of 138 was increased again by further addition of the IP agonist (Table I ). In the 138 genes, we focused on 22, which are known or have been suggested to be involved in the pathogenesis of arthritis (Table II) . We classifi ed these 22 genes into three groups based on their involvement in infl ammation, synovial proliferation, or bone and tissue destruction. The fi rst group consisting of seven genes is related to infl ammation and includes those for IL-11 (22) , IL-1 receptor, CSF receptor, CXC chemokine ligand 7 (23), CXC chemokine receptor 4 (24), and cytosolic phospholipase A 2 (25) . There were 10 genes related to the synovial proliferation, i.e., FGF-2 (26, 27), FGF-7, FGF-18, vascular endothelial growth factor (VEGF; references 26 and 28), and hypoxia inducible factor 1α, syndecan 1 (29), chondroitin sulfate proteoglycan 2 (29), hyaluronan synthase 1, hyaluronan synthase 2 (30), and UDP-N-acetylglucosamine pyrophosphorylase 1. Five genes were identifi ed as those related to bone and tissue destruction. They are genes for receptor activator of NF-κB ligand (RANKL; references 31 and 32), vitamin D receptor, a disintegrin and metalloprotease 8 (33), a disintegrin and metalloprotease with thrombospondin motifs 1, and a disintegrin and metalloprotease with thrombospondin motifs 5 (34) . To confi rm and quantify the eff ects of the IP signaling on the expression of these genes, we performed ARTICLE real-time RT-PCR analysis on genes for IL-11, VEGF, and RANKL (Fig. 5 A) . Consistent with the microarray analysis, the treatment with indomethacin signifi cantly decreased expression of these genes and the additional treatment with the IP agonist reversed this inhibition. To examine a possibility that these actions of the IP signaling were secondary to IL-6 production, we added exogenous IL-6 to synovial fi broblasts and examined its eff ects on the expressions of those genes. We found that the addition of IL-6 did not change the expression level of these genes (unpublished data), suggesting that expression of the above genes is regulated by the IP signaling independent of IL-6. Next, we examined whether the absence of the IP signaling aff ects the expression of these genes in vivo. As expected, the expression of IL-11, VEGF, and RANKL were signifi cantly decreased in the arthritic paws of IP −/− mice compared with that of WT mice (Fig. 5 B) . These results suggest that the PGI 2 -IP signaling promotes progression of CIA by enhancing the expression of IL-6 and other arthritisrelated genes in synovial fi broblasts.
Identifi cation of EP receptor subtypes working in the elicitation phase of CIA
We have thus clarifi ed the role of PGI 2 -IP signaling in the development of CIA. However, although the CIA score was signifi cantly suppressed by the loss of IP, there was still a small extent of infl ammation remaining in IP −/− mice. To examine if other PG signaling contributes to this remnant infl ammation, we treated IP −/− mice with indomethacin from day 21. We found that administration of indomethacin abolished the arthritis in IP −/− mice almost completely (Fig. 6 A) . These results suggest that PG signaling other than the PGI 2 -IP pathway also works in progression of CIA. The attenuation of IL-6 production by IP −/− synovial fi broblasts with indomethacin in vitro described above (Fig. 4 A) also supports this possibility. Because plenty of evidence supports the role of PGE 2 in RA (14, 15), we suspected that PGE 2 plays a role in this process and wanted to identify PGE receptor subtypes involved. Therefore, we backcrossed mice defi cient in each of the four subtypes of the PGE receptor (EP1 −/− , EP2 −/− , EP3 −/− , and EP4 −/− ) individually to the DBA/1J background for 10 generations. Because EP4 −/− mice could not survive in this background because of the patent ductus arteriosus (35), we administered an EP4-selective antagonist (ONO-AE3-208) at a dose of 10 mg/kg/day to evaluate the role of the EP4 receptor in CIA. This dose of the drug was previously shown to be suffi cient in suppressing EP4 functions in vivo (19) . When EP1 −/− , EP2 −/− , or EP3 −/− DBA/1J mice were subjected to CIA, all of these strains of mice developed swelling and erythema in the paws comparable to those in WT mice (Fig. 6 B) . Moreover, the administration of the EP4 antagonist during the elicitation phase elicited little eff ect on the arthritic symptoms of WT mice (Fig. 6 C) . Thus, despite the reduced CIA responses in mPGES-1 −/− mice (15), loss or inhibition of a single EP subtype alone does not signifi cantly aff ect the progression of CIA, suggesting a redundancy among the EP subtypes.
Because the PGI 2 -IP pathway uses the cAMP generation as a major signaling pathway and both EP2 and EP4 share this signaling, we suspected that EP2 and EP4 work redundantly to mediate PGE 2 action in CIA and either one of the two can Vehicle or EP4 antagonist (10 mg/kg/day) was administered from day 21. *, P < 0.05 versus vehicle-treated mice. (E) Effects of the IP agonist (1 μM cicaprost), the EP1 agonist (1 μM ONO-DI-004), the EP2 agonist (1 μM butaprost), the EP3 agonist (1 μM AE248), and the EP4 agonist (1 μM ONO-AE1-329) on IL-6 production in synovial fi broblasts. Synovial fi broblasts were treated as indicated, and IL-6 production was measured as described above. Results are expressed as the mean ± SEM (n = 3). *, P < 0.05 for the indicated comparison. Data shown are representative of at least three experiments.
compensate for the loss of the other. To test this hypothesis, we administered the EP4 antagonist to EP2 −/− mice during the elicitation phase in CIA. Administration of the EP4 antagonist reduced the arthritic score signifi cantly compared with that found in the vehicle-treated control EP2 −/− mice (Fig. 6 D) . These results support our hypothesis that EP2 and EP4 works redundantly for elicitation of CIA. Consistently, when agonists selective to each of the EP subtypes were added to the synovial fi broblast culture to examine their activity to enhance the IL-1β-stimulated IL-6 production, the compounds selective to EP2 and EP4, but not those to EP1 and EP3, potently enhanced the IL-6 production (Fig.  6 E) . The EP2 and EP4 agonists also share the activity to enhance production of IL-11, VEGF, and RANKL in this in vitro culture system (unpublished data).
DISCUSSION
The importance of PGs in the pathogenesis of RA has long been recognized through the wide use of NSAIDs for RA treatment (36, 37) . Indeed, a large amount of PGI 2 and PGE 2 was detected in the synovial fl uid of arthritic joints, suggesting the actions of these PGs in infl ammatory sites (13) . However, how each PG, PGI 2 in particular, works in RA remains largely unknown. To examine this issue, we used CIA as a mouse model for RA and subjected IP −/− mice in the DBA/1J background to this model. We have found that IP −/− mice exhibited signifi cantly reduced clinical and histological arthritic scores compared with control mice, demonstrating the importance of PGI 2 -IP signaling in the pathogenesis of CIA. This is an interesting result because PGI 2 has been considered as a mediator of acute infl ammation by causing vasodilation or enhancing vascular permeability, and less attention has been paid to the contribution of PGI 2 to chronic infl ammation. It has long been thought that PGE 2 is the primary PG responsible for infl ammation in RA. Our results indicate, however, that PGI 2 works as much as PGE 2 in the progression of CIA. IP −/− mice showed signifi cantly reduced arthritic scores in CIA despite the level of anti-CII titers comparable with WT mice and also exhibited reduced responses in CAIA, indicating that the PGI 2 -IP pathway works in the antibody-dependent eff ector mechanisms of joint infl ammation.
There are two arms of cell populations possibly mediating the IP action in the eff ector mechanisms: the bone marrowderived cell population, such as macrophages and neutrophils, and the mesenchymal cell population, such as synovial fi broblasts. Here, we have focused on the action of IP in synovial fi broblasts. We have found that the IP signaling working with IL-1β enhances IL-6 production from activated synovial fi broblasts. IL-6 has been suggested to exert many actions in the pathogenesis of RA, such as B cell maturation, synovial proliferation, and osteoclast formation (8, 38) . IL-6 −/− mice showed reduced arthritic lesions in CIA (39) , and the administration of anti-IL-6 receptor monoclonal antibody to RA patients resulted in a signifi cant improvement of both clinical symptoms and laboratory fi ndings (40) . Other than IL-6, PGI 2 -IP signaling induces a variety of arthritis-related genes, including IL-11, VEGF, FGF-2, and RANKL. IL-11 is a member of the IL-6 family and exerts proinfl ammatory eff ects in an acute methylated BSA/IL-1-induced arthritis model (22) . VEGF and FGF-2 stimulate angiogenesis, and the blockade of their signals results in reduced arthritis severity (27, 28) . RANKL is essential for osteoclast formation and mediates bone destruction (31) . These fi ndings strengthen our hypothesis that the IP-dependent activation of synovial fi broblasts plays a signifi cant role in the eff ector mechanisms of infl ammation in the joint. It should be mentioned that IP signaling can induce expression of these genes only in combination with IL-1β, and the stimulation of IP alone induces a signifi cant but marginal eff ect. The requirement of such synergism with IL-1β well explains the lack of arthritic symptoms in patients treated with an IP agonist, such as iloprost as a vasodilator. The lack of IP signaling and consequent impairment in synovial lining hyperplasia may aff ect the amount of chemokine production, such as MCP-1, from synovial fibroblasts and reduce the further infi ltration of infl ammatory cells. The signifi cantly lower concentration of IL-1β in the paws of arthritic IP −/− mice might be due to the impaired network of cytokine and chemokine signaling between synovial fi broblasts and infl ammatory cells. Collectively, our current fi ndings suggest that the PGI 2 -IP signaling in synovial fi broblasts works as an amplifi er of the infl ammatory processes in the joint through the induction of various arthritis-related genes. Whether and how the IP signaling in the bone marrow-derived cell population contributes to this process will be examined in bone marrow chimera in our future study.
Our study also points to the role of both PGE 2 and PGI 2 in the progression of CIA. For example, although the CIA score was signifi cantly suppressed by the loss of IP, there was still a small extent of infl ammation remaining in IP −/− mice. Our analysis for EP signaling indicates that this remaining infl ammation is mediated by PGE 2 via EP2 and EP4. Using mice defi cient in the EP subtypes individually as well as the EP4-selective antagonist, we found that although loss or inhibition of a single EP does not aff ect the extent of CIA, simultaneous inhibition of EP2 and EP4 signifi cantly reduced the arthritic score in CIA. These results suggest that EP2 and EP4 redundantly mediate the PGE 2 action in joint infl ammation and that these PGE 2 signaling pathways work together with the IP signaling to induce a full extent of CIA. It is quite likely that EP2 and EP4 also mediate infl ammation by activating synovial fi broblasts and promoting expression of arthritis-associated genes because these EP receptors share the cAMP signaling pathway with IP, and the agonists selective to EP2 or EP4 potently stimulate the expression of genes for IL-6, IL-11, RANKL, and VEGF in synovial fi broblasts in vitro. We also observed that IP −/− mice showed a signifi cantly reduced arthritic score in CAIA. Involvement of EP4 in CAIA was reported previously (41, 42) . Therefore, evidence now exists for a signifi cant role for both PGE 2 and PGI 2 in both models of arthritis. Which PG or PG receptor plays a predominant role in vivo may depend on the context of ARTICLE arthritis, which can determine the species of the PG(s) produced in arthritic joints.
The fi ndings described above naturally have an impact on the strategy for the development of anti-RA drugs. Although NSAIDs have been widely used for RA patients, gastrointestinal toxicity associated with the inhibition of the COX-1 isoform limits their use. To circumvent this problem, selective COX-2 inhibitors have been introduced and rapidly gained popularity (43) . However, one of the selective COX-2 inhibitors, rofecoxib, has recently been withdrawn from clinical use because a placebo-controlled trial revealed a signifi cant rise in the rate of cardiovascular accidents in rofecoxib users (44) . A major cause for such accidents is proposed to be the inhibition of COX-2-dependent PGI 2 production from endothelial cells. Indeed, it was shown experimentally that selective inhibition of the PGI 2 -IP signaling led to the acceleration of atherosclerosis and thrombosis (16, 45) . Therefore, this study suggests a possibility that both benefi cial and adverse eff ects of COX-2 inhibitors in RA come at least in part from the same mechanism; i.e., inhibition of PGI 2 synthesis. Given the clinical effi cacy of COX-2 inhibitors in RA patients and the current belief that PGE 2 is the major PG working in the pathogenesis of RA, several attempts are now in progress to develop selective inhibitors of mPGES, which is regulated similarly to COX-2 and, hence, is believed to work pre ferentially in infl ammation. This study on CIA, however, suggests that PGI 2 also works signifi cantly in RA, providing a cautious note that mPGES inhibitors may not be so eff ective in RA as COX-2 inhibitors.
MATERIALS AND METHODS
Materials.
Mice lacking the IP, EP1, EP2, EP3, and EP4 receptor individually were generated as described previously (16, 35, 46, 47) and backcrossed 10 times to DBA/1JNcr (Japan Charles River). Mice were bred at the Institute of Laboratory Animals of Kyoto University on a 12-h light/dark cycle under specifi c pathogen-free conditions. All experimental procedures were approved by the Committee on Animal Research of Kyoto University Faculty of Medicine. An EP4 antagonist, ONO-AE3-208 (AE3-208), was provided by Ono Pharmaceutical Co. The structures, binding affi nities, selectivities, and pharmacokinetic properties of AE3-208 have been described (19) . Indomethacin was purchased from Sigma-Aldrich.
CIA. CIA was induced in 5-6-wk-old male mice. Bovine CII (Cosmo-Bio) was emulsifi ed with CFA (Difco). Mice were immunized with the emulsion containing 100 μg CII by intradermal injection at the base of the tail on day 0 and boosted with 100 μg bovine CII emulsifi ed with IFA (Difco) on day 21. The extent of arthritis was evaluated by eye and scored according to the method as essentially described (48) . In brief, the arthritic lesion of each paw was graded on a scale of 0-4: 0, no change; 0.5, swelling and erythema of one digit; 1, swelling and erythema of two or more digits or slight swelling of the ankle or wrist joint; 2, mild swelling and erythema of the ankle or wrist joint; 3, severe swelling and erythema of the entire paw; 4, severe swelling and erythema with deformity of the entire paw.
CAIA.
Mice were injected i.p. with a mixture of anti-CII monoclonal antibodies (2 mg/500 μl/mouse; Chondrex) on day 0, and 3 d later, LPS (50 μg/ 100 ̣ μl/body; Escherichia coli. 0111:B4; Chondrex) was injected i.p. Arthritis was scored as described for CIA.
Histological examination. Hind paws were fi xed in 10% neutral-buff ered formalin, decalcifi ed in 10% EDTA in PBS, and embedded in paraffi n. Sections of 7-μm thickness of the knee joint were stained with either H&E or toluidine blue at pH 4.5. Two observers blinded to the genotypes of the preparations examined the sections and scored them. Scoring was based on the degree of lining hyperplasia, infl ammatory cell infi ltration in the joint cavity, and tissue destruction on a scale of 0-3 (0, within normal limits; 1, minimal; 2, mild; 3, severe) essentially as described previously (25) . As for tissue destruction, proteoglycan depletion, cartilage destruction, and bone destruction were scored separately, and the average of the scores of the three parameters was used to represent tissue destruction.
To examine complement deposition on the bone surface, the decalcifi ed hind paw preparation was soaked with 7.5% polyvinyl pyrrolidone in PBS and frozen at −80°C. 10-μm thick sections of the knee joint treated with Peroxo-Block (Zymed Laboratories) were incubated with rabbit antimouse C3 antibody (Hycult Biotechnology) in PBS with 10% goat serum (Sigma-Aldrich) at 4°C overnight, and then with horseradish peroxidaseconjugated polyclonal goat anti-rabbit IgG antibody (DakoCytomation) at room temperature for 2 h. The color was developed with diaminobenzidine tetrahydrochloride (Wako).
ELISA for anti-CII antibodies. A 96-well plate for ELISA (Sumitomo Bakelite) was coated with 5 μg/ml bovine CII in PBS overnight at 4°C. After nonspecifi c binding was blocked with 1% BSA (Sigma-Aldrich) in PBS for 2 h at room temperature, the diluted serum was added and incubated overnight at 4°C. After washing with 0.05% Tween 20 in PBS, either goat anti-mouse IgG, IgG1, IgG2a, or IgG2b antibody conjugated with alkaline phosphatase (SouthernBiotech) was added and incubated for 1 h at room temperature. The wells were washed and p-nitro-phenyl phosphate (Sigma-Aldrich) was added as a substrate. The color developed was determined by absorbance at 405 nm. Standard curves (in arbitrary units) for anti-CII IgGs were constructed from the pooled serum of a DBA/1J mouse with a high score of CIA. The titer of the standard serum was defi ned as 10,000 units/ml.
Isolation and culture of synovial fi broblasts. Synovial fi broblasts were isolated and cultured essentially as described previously (49) . In brief, the synovium of the knee joint from unimmunized control mice was dissected and then digested with 1 mg/ml collagenase A (Roche Diagnostics) in serum-free RPMI 1640 medium at 37°C for 2 h. The tissue digests were suspended and passed through nylon mesh. Dissociated cells were washed three times in RPMI 1640 medium containing 50 μM 2-mercaptoehtanol, 5 mM sodium pyruvate, and 10% heat-inactivated FCS, and cultured. After overnight culture, nonadherent cells were removed. At confl uence, cells were trypsinized, divided into three, and replated. The passage was repeated three to four times before use.
Synovial fi broblasts were plated at a density of 2 × 10 4 cells/well in a 96-well plate in RPMI 1640 medium with 1% FCS and cultured with or without mouse rIL-1β (R&D Systems). Indomethacin (Sigma-Aldrich) and either cicaprost, iloprost (Cayman), ONO-DI-004, butaprost (Cayman), ONO-AE-248, or ONO-AE1-329 was further added at the indicated concentration either alone or in combination. The ONO-DI-004, ONO-AE-248, and ONO-AE1-329 were supplied by ONO Pharmaceutical. The ligand-binding specifi cities of these compounds for each PGE receptor subtype have been described (14) . Supernatants were collected after 24 h of incubation. For RNA extraction, cells were plated at a concentration of 10 6 cells/dish in a 60-mm dish. Cells were isolated after 6 h. For some experiments, 10 ng/ml IL-6 (Calbiochem) was added instead of IL-1β.
Arthritic cell suspension was also prepared from the knee joints from mice on day 35 of CIA in the same way as described for synovial fi broblasts. The arthritic cell suspension was used without passage. The cells were plated at a concentration of 2 × 10 4 cells/well in a 96-well plate, and supernatants were collected after 24 h of incubation. For IL-1β measurement, 1 μg/ml LPS (E. coli S16B5; Sigma-Aldrich) was added.
Cytokine assays. The amount of IL-6, IL-1β, and TNF-α in culture supernatants and tissue homogenates was measured with ELISA kits (Endogen). The amount of MCP-1 in tissue homogenates was measured with ELISA kits (Biosource). For assays of cytokines in arthritic paws, samples were prepared as described previously (50) . DNA microarray analysis. Total RNA was prepared from synovial fi broblasts by using an RNeasy Mini kit (QIAGEN) and subjected to microarray analysis using a Mouse Genome 430A 2.0 Array (Aff ymetrix). Data were analyzed by Statistical Algorithm with the Aff ymetrix GeneChip Expression Analysis software (Microarray Suite 5.0). All microarray data are deposited in the Gene Expression Omnibus (GSE2676).
Quantitative real-time RT-PCR. Total RNA was obtained from arthritic paws using TRIzol reagent (Invitrogen). Complementary DNA was synthesized using Superscript II (Invitrogen). The amount of each mRNA for RANKL, IL-11, VEGF, and GAPDH was quantifi ed by real-time RT-PCR using LightCycler 2.0 (Roche Diagnostics). The primer sequences RANKL, VEGF, and GAPDH were described previously (51) (52) (53) . Primers used for IL-11 were 5′-G A C T C T G G A G C C A G A G C T G -3′ (forward) and 5′-G G G A T C A C A G G T T G G T C T G -3′ (reverse). Data were analyzed by LightCycler Software Version 4.0.
Statistics. Data are presented as the mean ± SEM. The comparison of two groups was analyzed using Student's unpaired two-tailed t test or the MannWhitney U test. For comparison of more than two groups, one-way ANOVA was performed fi rst, and either Dunnett's or Tukey's test was used to evaluate pairwise group diff erence. Two-way ANOVA was performed for comparison including two factors. A p-value of <0.05 was considered statistically signifi cant. The analyses were performed with the use of PRISM 4.0 software (GraphPad). Table S1 shows the number of genes in each cluster of microarray analysis and is available at http://www.jem.org/ cgi/content/full/jem.20051310/DC1.
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